Пертузумаб (Перьета), Трастузумаб (Герцептин)
Проводит Ф.Хоффманн-Ля Рош Лтд.
Страница компанииНе сравнительное открытое многоцентровое дополнительное исследование пертузумаба, применяемого в качестве монотерапии или комбинации с другой противоопухолевой терапией у пациентов, ранее включенных в исследование пертузумаба, спонсируемое компанией Ф. Хоффманн-Ля Рош
Постоянная ссылка: https://clinomir.ru/trials/permit/ru/496/2018-09-25/
Источник: ГРЛС — Государственный реестр лекарственных средств Минздрава России; ClinicalTrials.gov (U.S. National Library of Medicine); Расчёт Клиномира. Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 2 чел. в стране «Россия».
- Центров в реестре: 2 в 2 городах. Список — ниже на странице.
- Плановая дата окончания (12.2025) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 3 · невключение: 12
Критерии включения
- Informed consent
- Prior eligibility for, and receiving pertuzumab as an investigational medicinal product in, a Roche-sponsored study (either as a single agent or in combination with other anti-cancer drugs used in the Parent study) at the time of the Parent study closure
- Investigator's opinion that the patient continues to benefit from treatment
Критерии невключения
- Meets any of the exclusion criteria of the Parent protocol at the time the patient is considered for entry in the extension study
- Evidence of disease progression assessed according to Parent protocol before enrollment in to the extension study
- Permanent discontinuation of pertuzumab for any reason during the Parent study, or between the end of the Parent study and before enrollment into the extension study
- Any unresolved or irreversible toxicities during the Parent study that require permanent discontinuation of pertuzumab, according to Parent protocol or local label. Delay of treatment to wait for resolution of toxicities is allowed as long as it is within the guidelines of the respective Parent protocol and does not contradict exclusion criterion below.
- More than 9 weeks between the last dose of pertuzumab in the Parent study and the first dose pertuzumab in the extension study
- Left ventricular ejection fraction </= 50%
- Any serious uncontrolled concomitant disease that would contraindicate the use of pertuzumab or that would put the patient at high risk for treatment-related complications
- Treatment with any anti-cancer treatment (other than any treatment given as permitted in the Parent protocol) in the time period between last treatment in the Parent study and the first dose pertuzumab in the extension study (i.e. up to 9 weeks)
- Positive serum pregnancy test
- Women of child-bearing potential and men with partners of childbearing potential who do not agree to use a highly-effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by the patient and/or partner for the duration of study treatment and for at least 7 months after the last dose of study medication. Male patients who do not agree to refrain from donating sperm during this same period. Male patients whose partner is pregnant who do not agree to use condoms for the duration of the pregnancy.
- Concurrent participation in any therapeutic clinical trial (other than the Parent study)
- Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol
Источник: ClinicalTrials.gov, NCT02320435 · запись обновлена в реестре 6 ноября 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (6)
- Progression-Free Survival — From date of first dose of pertuzumab in this study until the date of disease progression or death, whichever occurs first (up to approximately 10 years)
- Overall Survival — From date of first dose of pertuzumab in this study until the date of death (up to approximately 10 years)
- Number of Participants with Adverse Events by Severity, Classified According to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 — From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
- Number of Participants with Adverse Events Leading to Pertuzumab Discontinuation or Dose Interruption — From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
- Number of Participants with Non-Serious Adverse Events of Special Interest (AESIs) — From Baseline until 7 months after the last dose of pertuzumab (up to approximately 10 years)
- Left Ventricular Ejection Fraction (LVEF) Over Time — Baseline, every 3 treatment cycles (1 cycle is 21 days), and 28 days after last dose of pertuzumab (up to approximately 10 years)
Цель исследования
This is a single-arm, multi-center, open-label extension study designed to provide continued pertuzumab therapy to patients receiving pertuzumab as an investigational medicinal product (IMP) in a Roche-sponsored global study and who continue to receive pertuzumab at the end of the Parent study, as well as to collect long-term safety and efficacy data of pertuzumab therapy. Patients with solid tumors who have not experienced progressive disease in the Parent study and, in the investigator's opinion, may potentially benefit from continued pertuzumab treatment, will continue to receive pertuzumab until disease progression, unacceptable toxicity, investigator/patient decision, patient non-compliance, patient death, patient request to withdraw, or study termination by the Sponsor, whichever occurs first.
Области и заболевания
Где проходит
2 центра в 2 городахОткуда эта информация
-
ГРЛС — Государственный реестр лекарственных средств Минздрава России · № 496 от 25.09.2018 Официальный реестр · загружено 1 октября 2026Препарат, номер протокола, название, разрешение, фаза, сроки, число участников, спонсор, разработчик
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT02320435 Официальный реестр (США) · загружено 9 ноября 2026Цель, центры
-
Расчёт Клиномира По датам из реестраСтатус
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.